New pharmaceutic aims at emergents
DCI - 04/17/2008
With investments of Votorantim Novos Negócios and the American Texas Pacific Group (TPG), Moksha8, a new pharmaceutic global company located in China, started its operations focusing the emerging markets, specially the BRIC countries :Brazil, Russia, India and China. The company which chose Brazil as the first Country for the development of its business intends to become the greatest pharmaceutical company of the Country in the next three years. This period seem to be too small for a newcomer, but the company guarantees that it will have strong performance in the market segment of biotechnology medicines in Brazil. In this sense, moksha8 (written in small letters) foresees investing up to US$ 500 million in the construction of one or more plants in Brazil in the next five years. In a first phase, already started this week, the company will promote more than 20 Pfizer and Roche medicines to the sector of medical prescription, among which Bactrim, Lexotan, and Diabinese. In 2009, the company will work in the licensing of new products, patented by small- and mid-sized pharmaceutical laboratories and biotechnology companies, and in the distribution of the medicines of these companies, already with its brand. According to global vice-president and moksha8's leader for Latin America, Mario Grieco, the choice of working in emerging countries was strategical. «moksha8 focuses to provide the emerging markets with high-technology medicines. These markets have been demanding better quality medicine, although these regions have low importance for global investors », affirmed Grieco. Grieco also affirms that the choice to start the operations in Brazil was due to the potential of the market and the best quality of the regulatory and patentes system. The executive also said that the offer of byotechnological medicines are stronger in developed countries and that the new company will bring up these products to the emerging markets. « Traditionally, the multinational pharmaceutical companies have their main focus in developed markets, thus there is no immediate interest in offering them in countries like Brazil», completed Grieco.